Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD

European Respiratory Journal

Volumn 49, Issue 4, 2017, Pages

  O’Donnell, Denis E ^a   Casaburi, Richard ^b   Frith, Peter ^c   Kirsten, Anne ^d   De Sousa, Dorothy ^e   Hamilton, Alan ^e   Xue, Wenqiong ^f   Maltais, François ^g  

^a QUEEN S UNIVERSITY   (Canada)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c Central Adelaide Local Health Network   (Australia)

^d GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^e BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BRONCHODILATING AGENT; TIOTROPIUM-OLODATEROL;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG WITHDRAWAL; DYSPNEA; ENDURANCE TRAINING; FEMALE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIOTROPIUM BROMIDE;

EID: 85031113865     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01348-2016     Document Type: Article

References (35)

1. ZuWallack R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD 2007; 4: 293–297.
2. Jones PW. Activity limitation and quality of life in COPD. COPD 2007; 4: 273–278.
3. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4: 225–236.
4. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506–512.
5. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014; 44: 1521–1537.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2016. www.goldcopd.org Date last accessed: November 11, 2016.
7. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211–277.
8. Borel B, Provencher S, Saey D, et al. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med 2013; 2013: 410748.
9. Fotheringham I, Meakin G, Punekar YS, et al. Comparison of laboratory- and field-based exercise tests for COPD: a systematic review. Int J Chron Obstruct Pulmon Dis 2015; 10: 625–643.
10. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016; 47: 429–460.
11. O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–840.
12. O’Donnell DE, Hamilton AL, Webb KA. Sensory–mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 2006; 101: 1025–1035.
13. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168–1178.
14. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420–427.
15. Bédard M-E, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in COPD. Eur Respir J 2012; 39: 265–271.
16. Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013; 144: 490–497.
17. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
18. Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 1351–1361.
19. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat© in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 629–645.
20. Lange P, Aumann J-L, Hamilton A, et al. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med 2014; 4: 196.
21. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat© versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 697–714.
22. Maltais F, Kirsten A-M, Hamilton A, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies. Respir Res 2016; 17: 77.
23. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J 2015; 45: 969–979.
24. ERS Task Force on Standardization of Clinical Exercise Testing. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J 1997; 10: 2662–2689.
25. Hareendran A, Leidy NK, Monz BU, et al. Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 345–355.
26. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6: Suppl. 16, 5–40.
27. O’Donnell DE, Travers J, Webb KA, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J 2009; 34: 866–874.
28. O’Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86–94.
29. Beeh K-M, Westerman J, Kirsten A-M, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015; 32: 53–59.
30. O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030–1036.
31. Beeh K-M, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014; 108: 584–592.
32. Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 2014; 8: 169–181.
33. Magnussen H, Paggiaro P, Schmidt H, et al. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med 2012; 106: 1413–1420.
34. Saey D, Debigaré R, Leblanc P, et al. Contractile leg fatigue after cycle exercise. A factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 425–430.
35. Deschênes D, Pepin V, Saey D, et al. Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev 2008; 28: 208–214.